Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Varian Medical Systems and Johnson & Johnson Innovation – JJDC have returned for the series C-1 round having backed the U-M spinout's series C last year.

Genscript Biotech's multiple myeloma-focused spinoff, which counts Eli Lilly and Johnson & Johnson among its investors, has completed an initial public offering in the US.

Eli Lilly will collaborate on five drug candidates based on the Oxford and Karolinska Institute spinout's exosome delivery technology.

Existing backer GV returned to take part in a $100m round for the clinical data software provider that also attracted new investor Regeneron Pharmaceuticals.

Johnson & Johnson and Varian Medical Systems are in line for exits after cancer therapy developer Fusion filed for a $100m initial public offering.

The cancer diagnostics technology developer, formed five years ago when Qiagen acquired part of Enzymatics, has filed to float on the Nasdaq Global Market.

Varian Medical Systems and Johnson & Johnson Innovation – JJDC returned for the series C-1 round having backed the histotripsy technology developer's series C last year.

McMaster University spinout Fusion Pharmaceuticals has filed for a $100m IPO in the US, putting shareholders such as Facit in line for exits.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.